Form 10-Q Pacira Pharmaceuticals, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Pacira Pharmaceuticals (PCRX) PT Raised to $50 at RBC Capital
August 3, 2018 7:56 AM EDTRBC Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $50.00 (from $44.00) while maintaining a Outperform rating.
... MoreNeedham & Company Upgrades Pacira Pharmaceuticals (PCRX) to Buy; 'All Signs Point to a Significant Exparel Growth Inflection'
August 3, 2018 7:27 AM EDTNeedham & Company upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Hold to Buy with a price target of $54.00.
Analsyt Serge Belanger commented, " Exparel's strong 2Q18 performance ($80.4MM, +15%Yr/ Yr) appears to be accelerating with sales growth of 16%Yr/Yr in May and 18%Yr/Yr... More
Pacira Pharmaceuticals (PCRX) PT Raised to $40 at BMO Capital
August 3, 2018 6:57 AM EDTBMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $40.00 (from $34.00) while maintaining a Market Perform rating.
Analsyt Gary Nachman commented, "PCRX reported 2Q18 non-GAAP revenue of $81mmabove BMO/consensus $77mm/$76mm, and EPS of $0.24 above BMO/consensus $0.09/$0.07. Solid 2Q... More
